William T. Symonds
Vorstandsvorsitzender bei Altavant Sciences, Inc.
Profil
William T.
Symonds is currently the Chief Executive Officer at Enzyvant, Inc. and Enzyvant Therapeutics GmbH.
He also holds the position of Director, Chief Executive & Development Officer at Altavant Sciences, Inc. Previously, he served as the Executive Director & Chief Development Officer at Arbutus Biopharma Corp.
from 2015 to 2018.
Prior to that, he was the Director at Arbutus Biopharma, Inc. from 2014 to 2015.
He has also worked as the Director-Antiviral Clinical Pharmacology at GlaxoSmithKline LLC.
In addition, he held the position of Vice President-Liver Disease Therapeutic at Gilead Sciences, Inc. in 2014.
From 2007 to 2012, he served as the Senior Vice President-Clinical Pharmacology at Pharmasset, Inc. He has also worked as the Chief Development Officer at Roivant Sciences GmbH and Roivant Sciences, Inc. Dr. Symonds holds a doctorate degree from Campbell University.
Aktive Positionen von William T. Symonds
| Unternehmen | Position | Beginn |
|---|---|---|
Altavant Sciences, Inc.
 Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Vorstandsvorsitzender | 01.08.2018 |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Vorstandsvorsitzender | 11.03.2022 |
Enzyvant Therapeutics GmbH
 Enzyvant Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Enzyvant Therapeutics GmbH is a Swiss biotechnology company that focuses on developing treatments for rare diseases. The company is based in Basel, Switzerland. William T. Symonds has been the CEO of the company since 2022. | Vorstandsvorsitzender | 01.01.2022 |
Ehemalige bekannte Positionen von William T. Symonds
| Unternehmen | Position | Ende |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 22.10.2018 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.07.2018 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Direktor/Vorstandsmitglied | 01.03.2015 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.04.2014 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01.01.2012 |
Ausbildung von William T. Symonds
| Campbell University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Altavant Sciences, Inc.
Altavant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC. | Health Technology |
Enzyvant Therapeutics GmbH
Enzyvant Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Enzyvant Therapeutics GmbH is a Swiss biotechnology company that focuses on developing treatments for rare diseases. The company is based in Basel, Switzerland. William T. Symonds has been the CEO of the company since 2022. | Commercial Services |
